摘要
目的：观察加减黄连温胆汤对膳食诱导的MS大鼠的干预作用，并以脂肪细胞因子和内皮功能为切入点探讨该药作用的分子机制。
方法：雄性SD大鼠60只随机分为两组，正常组10只，实验组50只，分别予普通饲料和高脂高糖高盐饲料饲喂20周。成模的37只MS大鼠，随机分为模型组、加减黄连温胆汤高、低剂量组，二甲双胍对照组、灌服相应药物4周。动态测量体重、血压、空腹血糖、FINS、血脂等指标，计算HOMA-IR，进行模型及药物作用评价。药物干预前后观察各组大鼠主动脉病理变化(HE染色法)，采用ELASA法测量各组大鼠血清vWF因子；放免法检测血清脂肪酸、瘦素、肿瘤坏死因子、白介素-6、脂联素水平；RT-PCR检测脂肪组织脂联素mRNA的表达。
结果：饲喂20周末，实验组大鼠体重、腹围、Lee′s指数、血压、空腹血糖、空腹胰岛素、HOMA-I R、血脂TG、TC以及LDL均明显增高，HDL水平减低，与正常组比较，经统计学分析，有显著性差异(P＜0．01)。
药物干预4周末，与模型组比较，加减黄连温胆汤高、低剂量组及二甲双胍组体重、血压均下降，其中加减黄连温胆汤高剂量组与二甲双胍组体重下降(P＜0．01)。加减黄连温胆汤高剂量组大鼠血压明显下降，与模型组比较有统计学意义(P＜0．05)。加减黄连温胆汤高剂量和二甲双胍组大鼠血糖出现不同程度下降(P_高＜0．05，P_(二甲)＜0．0 1)；加减黄连温胆汤高剂量组大鼠TG、TC和LDL-C水平均与模型组比较有显著性差异(P＜0．01)；加减黄连温胆汤高剂量组和二甲双胍组大鼠FINS水平均较模型组降低(P_(二甲)＜0．01，P_高＜0．05)；加减黄连温胆汤高剂量组和二甲双胍组大鼠胰岛素抵抗指数均下降，有显著性差异(P＜0．01)；加减黄连温胆汤高剂量组和二甲双胍组大鼠Lee’s指数、内脏脂肪重量及内脏脂肪与体重的比值均明显降低，有显著性差异(P＜0．01)。
主动脉H染色显示，MS模型组大鼠主动脉存在严重的内皮损伤；加减黄连温胆汤高剂量组、低剂量组、二甲双胍组有不同程度改善，以加减黄连温胆汤高剂量组改善最明显；与正常组比较，MS模型组血清vWF水平明显升高(P＜0．01)，与MS模型组相比，加减黄连温胆汤高、低剂量组vWF水平均明显降低(P＜0．01)。
与空白组比较，MS模型组血清FFA、瘦素、TNF-α、IL-6水平升高(P＜0．01)。药物干预4周末，与MS模型组相比，加减黄连温胆汤高、低剂量组、二甲双胍组FFA水平均明显降低(P＜0．01)；加减黄连温胆汤高剂量和二甲双胍组大鼠血清瘦素、TNF-α、IL-6浓度降低(P＜0．01)；与空白组相比，模型组ADPN水平和脂联素mRNA相对定量基因表达显著减低(P＜0．01)；与模型组比较，加减黄连温胆汤高剂量和二甲双胍组ADPN水平增高(P＜0．05)；加减黄连温胆汤高剂量组ADPN mRNA相对定量基因表达升高(P＜0．01)；二甲双胍组ADPN mRNA无显著性差异(P＞0．05)。
结论：
1．长期高脂高糖高盐饮食饲喂SD大鼠可成功复制MS大鼠模型，并且该模型具备人类MS的基本临床特征。
2．加减黄连温胆汤具有减重、降压、调脂、改善胰岛素抵抗作用，能够改善MS各组分，综合疗效优于二甲双胍，是防治MS的有效药物，值得进一步研究开发
3．MS大鼠存在内皮功能损伤，加减黄连温胆汤能降低血清vWF水平，改善MS大鼠主动脉组织结构，对血管内皮功能损伤具有改善作用。
4．加减黄连温胆汤具有降低MS大鼠血清TNF-α、IL-6水平，抑制炎症反应的作用。
5．加减黄连温胆汤能够降低MS大鼠血清FFA、瘦素、脂联素水平，促进脂联素mRNA表达，具有调节脂肪细胞因子的作用。
6．黄连温胆汤能够调节脂肪细胞因子表达、抑制炎症反应，这可能是该药改善MS血管内皮功能的机制之一。
Objective:To observe the effect of huanglianwendan decoction onmetabolic syndrome food-inducing rats,and Start with adipocyto-kines andendodermis function to discuss the molecular mechanism thathuanglianwendan decoction prevents and treats MS.
Method:Sixty 8-week-old male SD rats were randomly divided into 2groups which are vacuity group (n=10)and experimental group (n=50)vacuity group was fed with common diet,and experimental group was fedwith high lipid,high salt and high glucose diet for 20 weeks to induceexperimental metabolic syndrome.37 SD rats in experimental group whichwere modeled successfully were randomly divided into 4 groups:modelgroup huanglianwendan decoction high-dose group,low-dose group andMetformin Hydrochioride control group,which were lavaged with theappropriate drug for 4 weeks.Dynamic state measure weight,blood pressure,fasting blood glucose,serum insulin,lipids and other indicators,calculateHOMA-IR,to evaluate model and drug effect.Before and after drug therapy,we observed the pathological change of aorta by HE staining method,andtested:the vWF factor levels of serum by ELISA method;the level of FFA,LEP,TNF-α,IL-6 and ADPN in serum by RIA method;the expressions ofADPNmRNA in adipose tissue by RT-PCR method in each group.
Result:After feeding for 20 weeks,the weight,abdominalcircumference,Lee's index,blood pressure,fasting glucose,fasting insulin,HOMA-IR,lipids TG,TC and LDL of Experimental rats were significantlyhigher,HDL level of reduction,compared with the vacuity group,thedifference was significant (P＜0.01).
After 4 weeks treated with drugs,compared with the model group,theweight and blood pressure decreased in huanglianwendan decoction high andlow-dose group and the metformin group,in which huanglianwendandecoction high-dose group and metformin group weight loss significantly (P＜0.01).The blood pressure in Huanglianwendan Decoction high-dose groupdecreased obviously,compared with the model group,it was statisticallysignificant (P＜0.05).the blood glucose of huanglianwendan decoctionhigh-doses group and metformin group decreased with varying degrees (P＜0.01),(P＜0.05)Compared with the model group,there were remarkabledifferentce In the TG,TC and LDL-C level of huanglianwendan decoctionhigh doses group P＜0.01).The serum insulin levels of huanglianwendan decoction high-dose group and metformin group were lower than those inmodel group (P＜0.01),(P＜0.05).The insulin resistance index(HOMA-IR)in huanglianwendan decoction high-dose group and the metformin groupdecreased,and there was significantly difference (P＜0.01).The Lee's index,visceral fat weight,visceral fat and body weight ratio in huanglianwendandecoction high-dose group and the metformin group were significantlydecreased,the difference was remarkable (P＜0.01).
The MS model group rats had serious endothelial injury in aortic Hstaining;huanglianwendan decoction high-dose group,low-dose group andmetformin group,there are amelioration in endothelial injury with varyingdegrees;the huanglianwendan decoction high-dose group had the mostobvious amelioration.Compared with the vacuity group,the serum vWFlevels of MS model group were significantly higher (P＜0.01),comparedwith the MS model,the vWF level in huanglianwendan decoction high andlow dose group were lower significantly (P＜0.01).
Serum FFA,leptin,TNF-αand IL-6 concentration in MS model groupincreased,Compared with the vacuity group,the difference was obvious (P＜0.01);compared with the model group,the FFA level in the other threegroup decreased remarkably.serum leptin,TNF-α,IL-6 concentrations ofhuanglianwendan decoction high-dose group and metformin group ratsdecreased (P＜0.01).Compared with the vacuity group,the ADPN level landrelative quantitative gene expression of ADPNmRNA in model groupsignificantly reduced (P＜0.01);compared with the model group,the ADPNlevel of huanglianwendan decoction high-dose group and metformin groupincreased (P＜0.05);the relative quantitative gene expression of ADPNmRNA in huanglianwendan decoction high-dose group increased,(P＜0.01).the relative quantitative gene expression of ADPN mRNA in Metformingroup had no significant difference (P＞0.05).
Conclusion:1.High fat high sugar high salt diet feeding SD rats forLong term can copy the MS model with the basic human clinical features ofMS.
2.Huanglianwendan Decoction can loss weight,lower blood pressure,regulate lipid and improve insulin resistance,which can improve the variouscomponents of MS.The comprehensive effect of huanglianwendan decoctionis superior than that of metformin.Huanglianwendan decoction is aneffective drug on preventing and treating MS,which has the value to researchand develope further.
3.there is endothelial dysfunction in MS rats,but huanglianwendandecoction can reduce the level of serum vWF and improve the organizationalstructure of the MS rat aorta to improve vascular endothelial dysfunction.
4.Huanglianwendan decoction has the effect on reducing serum TNF-α,IL-6 levels of MS rats and inhibiting inflammatory response.
5.Huanglianwendan decoction can reduce the levels of FFA,leptin andadiponectin in the MS rats serum and promote the expression of adiponectinmRNA,which has obvious effect of regulating adipocytokines.
6.Huanglianwendan decoction can regulate the expression ofadipocyto-kines and inhibit inflammatory response,which may be one of themechanisms to improve vascular endothelial function in MS.
引文
[1]祝之明，徐成斌．应加强MS的研究和防治[J]．中华心血管病杂志，2005，33(2)：105-106．
[2]祝之明．MS研究现状和趋势[J]．解放军医学杂志，2005，30(8)：680-682．
[3]Definition,diagnosis and classification of diabetes mellitus and its complications:report of aWHO consultation.Part1:diagnosis and class ification of diabetes mellitus.Geneva,Switzerland,WorldHealth Organi zation,1999.Available at:http//whqlibdoc.who.int/hq/1999 /WHO-NCD-NCS-99.2.pd.f Accessed December 12,2003.
[4]Third report of the national cholesterol education program (NCEP)e xpertpanel on detection,evaluation,and treatment of high blood choles terol in adults (Adult Treatment PanelⅢ).Final report.Circulation,200 2,106:3143-3421.
[5]中华医学会糖尿病分会MS研究协作组．中华医学会糖尿病学会关于MS的建议[J]．中华糖尿病杂志，2004：12(3)：156-157．
[6]Alberti KG,Zimmet P,Shaw J.Metabolic syndrome-a new world-wid e definition.A Consensus Statement from the International Diabetes Fed eration[J].Diabet Med,2006,23:469-480
[7]Zimmet P,Alberti G,Kanfman F,et al.The metabolic syndrome in chil dren and adolescents[J].Lancet,2007,369,369(9579):2059-2061.。
[8]Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of Th e National Cholesterol Education Program (NCEP)Expert Panel on Det ection,Evaluation,And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel Ⅲ).JAMA,2001,285(19):2486-2497.
[9]Gu DF,Reynolds K,Wu XG,et al.Prevalence of the metabolic syn drome and overweight among adult in China[J].Lancet,2005,365:1398-1401,
[10]Sheu WH,Chuang SY,Lee WJ,et al.Predictors ofincident diabete s,metabolic syndrome in middle-agedadults:A 10-year follow-up study from Kinmen,Taiwan.Diabetes Res Clin Pract,2006,74:162-168
[11]Palaniappan L,Carnethon MR,Wang Y,et al.Predictors of the inc ident metabolic syndrome in adults:the InsulinResistance Atheroscleros is Study.Diabetes Care,2004,27:788-793.
[12]Wajchenberg BL,Giannella-Neto D,da-Silva ME,et al.Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue a nd their relation to the metabolic syndrome.Horm Metab Res,2002,34 (11-12):616-621.
[13]Grundy SM, Hansen B, Smith SC, et al.Clinical management of me tabolic syndrome: report of American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management [ J ] .Circulation, 2004, 109: 551-556.
[14]沈振海,陆昀,方宁远。MS 研究的新进展。 中国心血管病研究,2008, 6: 466-468.
[15]Anderson TJ. Assessment and treatment of endothelium dysfunction in humans. J Am Coll Cardiol, 1999, 34: 631-638.
[16]Bannerman DD, Goldblum SE. Direct effects of endotoxin on the endothelium: barrier function and injury. Lab Invest, 1999, 79: 1181 - 1199.
[17]Nagy J, Csiky B, Kov(?)cs T, et al. Endothelial dysfunction. OrvH etil, 2001 , 142: 1667 -1672.
[18]Esper RJ, Nordaby RA, Vilarino JO, et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol, 2006, 5: 4.
[19]Morooka T, Node K. Methods to evaluate the vascular endothelial function. Nippon Rinsho, 2006, 64: 2069-2073.
[20]Horstman LL, Jy W, Jimenez JJ, et al. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci, 2004, 9: 1118 - 1135.
[21]Fornoni A, Raij L. Metabolic syndrome and endothelial dysfunction. Curr Hypertens Rep, 2005, 7: 88-95.
[22]Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction. J Nephrol, 2007, 20: 10-14.
[23]Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endo thelium. Am J Med, 2004, 117: 109-117.
[24]Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 2006, 113: 1888-1904.
[25]Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res, 2003, 11: 1278 - 1289.
[26]Pinkney JH, Stebouwer CD, Coppack SW. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes, 1997, 46: s9-12.
[27]Winkler G, Lakatos P, Salamon F, et al. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med, 1999. 16: 207-211.
[28]Tripathy D, Aljada A, Dandona P. Free fatty acids (FFA) and end othelial dysfunction; role of increased oxidative stress and inflammation. To: Steinberg, et al. (2002) Vascular function, insulin resistance and fatty acids. Diabetologia, 2003, 46: 300-301.
[29]Nitenberg A. Hypertension, endothelial dysfunction and cardiovascular risk. Arch Mal Coeur Vaiss, 2006, 99: 915-921.
[30]ChicurelM. Whatever happened to leptin[J] Nature, 2000,404(6778):538-540.
[31] KimuraK, TsudaK, BabaA, et a.l Invol vementofnitric oxide in endot helium- -dependent arterial relaxation by leptin [ J].Biochem BiophysResCommun, 2000, 273(2): 745-749.
[32]QuehenbergerP, ExnerM, Sunder-PlassmannR, eta.l Leptin induces endothelin-1 in endothelial cells in vitro [ J]. CireRes, 2002, 90(6): 711-718.
[33]BouloumieA, MarumoT, LafontanM, eta.l Leptin induces oxidative stress in human endothelial cells[J]. FASEB J. 1999,13 (10): 1231-1238.
[34]杨义生,洪洁,顾卫琼,等。脂肪组织的 分泌功能与 MS [J].国外医学内分泌学分册, 2004, 24(3): 156-159.
[35]W inters B, Mo Z, Brooks-Asplund E, et a.l Reduction of obesity, as induced by leptin, reverses endothelial dysfunctionin obese (Lepob) mice [J]. J Appl Physio,1 2000, 89 (6):2382-2390.
[36]ParkH Y, KwonHM, Lim H J, et a.l Potential role of leptin in ang iogenesis: leptin induces endothelial cellproliferation and expression of matrixmetalloproteinases in vivo and in vitro[J].ExpMolMed, 2001, 33 (2): 95-102.
[37] FortunoA, RodriguezA, Gomez- Ambrosi J, eta.l Leptin inhibits angiotensinll- induced intracellular calcium increase and vasoconstriction in the rat aorta [ J]. Endocrinology,2002, 143 (9): 3555-3560.
[38]MatsudaM, Shimomura 1, SataM, et a.l Role of adiponectin in preventing vascular stenosis: themissing link of adipovascular axis[J]. JBiolChem, 2002, 277 (40): 37487-37491.
[39]OuchiN, Kihara S, FunahashiT, et al. Obesity, adiponectin and vascular inflammatory disease [J]. CurrOpin Lipido,2003, 14(6): 561-566.
[40] KumadaM, Kihara S, OuchiN, et al. Adiponectin specifically increa sed tissue inhibitor ofmetalloproteinase-1 through interleukin-10 expres sion in human macrophages[J].Circularton,2004,109(17):2046-2049.
[41]OuchiN,Kihara S,Arita Y,et a.l Adiponectin,an adipocyte-derive d plasma protein,inhibits endothelia TNF-kappaB signaling through a cAMP-dependent pathway[J].Circulation,2000,102(11):1296-1301.
[42]Chen H,MontagnaniM,Funahashi T,et a.l Adiponectin stimulates production ofnitric oxide in vascularendothelial cells[J]J BiolChem,2003,278(45):45021-45026.
[43]高小亚，戈敏娟，马向华．单纯性肥胖患者血清瘦素、抵抗素和脂联素水平的研究[J]．医学研究生学报，2006，19(6)：544-547．
[44]NishimuraH,TsujiH,Kasahara T,et al.The efects of angiotensinmetab olites on the regulation of coagulation and fibrinolysis in culcured rat arotic endothelial cell[J].Thromb Haemost,1999,82(5):1516-1521.
[45]GrafeM,Aueh-SctncelkW,GrafeK et a.l AngiotensinⅡ induced leukocy te adhesion on human conoraty endothelial cells is by E-selection[J].Ci rc Res,1997,81(5):804-811.
[46]Rueckschlos SU,Quinn MT,Holtz J,et a.l Dose dependent regulati on of NAD (P)H oxidase expression angiotensin lI inhuman endothelial cells:protective efect of angiotemin Ⅱ type lreceptor blockade in pati entswith conorary artery disease[J].ArteriosclerThromb Vasc Biol,2002,22(11):1845-1851.
[47]Uno H,Matsuyama T,Akita H,et a.l Induction of tumor necrosis factor-αin the mouse hippocampus following transient forebrain ischemi a[J].JCereb Blood FlowMetab,1997,17(5):491-499.
[48]Kagota S,Tanaka N,Kubato Y.Characteristic of vasorelaxation res ponses in a rat model of metabolic syndrome[J].Clin Exp Pharmacol Ph ysiol,2004,31(suppl 2):S54-S56.Cramer CT,Goetz B,Hopson KL,et al.Effects of a novel dual lipid synthesis inhibitor and its potential ut ility in treating dyslipidemia and metabolic syndrome[J].Lipid Res,2004,2004,45 (7):1289-1301.Hirao-Yamamoto J,Nara Y,Yasui N,et al.Establishment of a new animal model of metabolic syndrome:SHRSP fatty(fa/fa)rats[J].Clin Exp--Pharmacol Physiol,2004,31(1-2):107-109.
[49]Dellbose S,Paizanis E,Magous R,Involvement of oxidative stre ss and NADPH oxidase activation in the development of cardiovascular complications in a modelof insulin resistance,the fructose-fed rat[J].Atherosclerosis,2005,179(1):43-49.Aguilera AA,Diaz GH,Barcelata ML.Effects of fish oil on thpertension,plasma lipids,and tumor necro sis factor-alpha in rats with sucrose induced metabolic syndrome[J].Nut r biochem,2004,15(6):350-357.
[50]Eckel RH,Grundy SM,Zirnmet PZ.The metabolic syndrome[J].La ncet,2005,365:1415-1428.
[51]Kahn R.Metabolic syndrome-what is the clinical usefulness?[J].Lan cet,2008,371:1892-1893
[52]李庆生．诊治MS应重视痰瘀互结[J]．云南中医中药杂志，2007，28(2)：2-5．
[53]董静，王琦，王东坡，等．从痰湿体质角度论析MS[J]．北京中医药大学学报，2006，29(12)：802-803．
[54]张刚，祝之明，倪银星，等．MS危险因素的特征[J]．高血压杂志，2004，12(1)：83．
[55]仝小林，张志远．中医对MS的认识和治疗[J]．中医杂志，2002，43(9)：708-709．
[56]肖玲，凌玲．情志对糖尿病的影响初探[J]．河北中医，2002，24(1)：48-49．
[57]黄家荣．浅谈脾胃与MS[J]．浙江中医杂志，2006，41(2)：96-97．
[58]李锡杰，刘志龙．论从脾论治MS[J]．中医药导报，2006，12(4)：9-10，32．
[59]刘欣燕，朱德增．肝与MS[J]．山东中医杂志，2007，26(7)：493-494．
[60]王德玉．论肝与MS[J]．浙江中西医结合杂志，2004，14(1)：23-24．
[61]林飞，赵长安，赵涛，等．MS中医辨证的研究概况[J]．辽宁中医药大学学报，2008，10(2)：148-149．
[62]杨文学，高天舒．从肝脾论治MS[J]．吉林中医药，2007，27(12)：13-14．
[63]夏瑢．中医三焦气化理论的应用研究——一对糖尿病病变机制的再探索[J]．中华中医药学刊，2008，36(3)：532-534．
[64]张剑．从三焦与“毒”探讨MS[J]．中医杂志，2007，48(6)：487-489．
[65]曹忠贞．论消渴与痰[J]．中医药研究，1997，13(2)：8-9．
[66]谢维宁，杨钦河，纪桂元．MS的中医病因病机探讨[J]．时珍国医国药，2007，18 (3)：716-717．
[67]柴可大，王亚丽．从痰瘀论治IR[J]．中华中医药杂志，2005，20(9)：542-543．
[68]王如沾，曲卫毅．论毒与糖尿病[J]．山东中医杂志，1999，18(8)：339-341．
[69]中华医学会糖尿病学分会MS研究协作组．中华医学会糖尿病学分会关于MS的建议[J]．中华糖尿病杂志，2004，12(3)：156-161．
[70]张京春，陈可冀．MS与中西医结合综合干预[J]．中国中西医结合杂志，2004，24(11)：1029～1032．
[71]司福全．中医对MS的认识与防治．辽宁中医杂志，2006，33(9)：1107～1108
[72]刘惠文，张铁忠，李光伟，等．高血压病患者IR与中医辨证分型的相关性研究．中国中西医结合杂志1999，19(4)：200．
[73]李秋炎，贾太平，赵展荣，等．Ⅱ型糖尿病患者中医辨证分型与胰岛β细胞功能关系的研究．中医杂志1998，39(7)：428．
[74]朱章志，熊曼琪．Ⅱ型糖尿病患者不同证型红细胞胰岛素受体缺陷的观察．中国中西医结合杂志1995，15(5)：266-268．
[75]谢宗长，钱振坤，柳重威．人参抗实验性糖尿病大鼠脂质过氧化损伤的研究．中国中西医结合杂志，1993，13(5)：289-290．
[76]胡翠华，徐华丽，于晓风，等．人参二醇组皂苷对实验性2型糖尿病大鼠血糖及血脂代谢的影响．吉林大学学报(医学版)，2006，32(6)：1004-1008．
[77]Lee YS Kim WS,Kim KH,et al.Berberine,a natural plant produ ct,activates AMP-activated protein kinase with beneficial metabolic ef fect in diabetic and insulin-resistant states[J].Diabetes,2006,55(8):2256-2264.
[78]高从容，张家庆，黄庆玲．黄连素增加IR大鼠模型胰岛素敏感性的研究．中国中西医结合杂志，1997，17(8)：162．
[79]陆灏，叶伟成，丁学屏．黄连素对实验大鼠IR的影响．辽宁中医学院学报，2002，4(4)：259-260．
[80]刘永玉，毛良，莫启忠，等．实验性2型糖尿病大鼠的IR性．中国病理生理杂志，1991，7(4)：422-425．
[81]祁忠华，林善镁，黄宇峰，等．黄芪改善糖尿病肾病早期血流动力学异常的研究．中国糖尿病杂志，1999，7(3)：147-149．
[82]鲁瑾，邹大进，张家庆．黄芪预防肿瘤坏死因子-α所致IR．中国中西医结合杂志，1999，19(7)：420-422．
[83]金椿，戴瑞鸿，周峰，等．黄芪对冠心病患者红细胞内钠含量和钠转运的影响．中西医结合杂志，1991(11)：651-653．
[84]玉从容，吕俊华，王丹．葛根素抗氧化作用与改善IR综合征模型大鼠胰岛素敏感性、血压和血脂作用的实验研究．上海中医药杂志，2006，40(4)：53-55．
[85]庆方，潘竞锵，肖柳英，等．葛根素增强IR-高血压大鼠胰岛素敏感性作用机制研究．中国现代应用药学杂志，2006，23 (9)：868-871．
[86]徐梓辉，周世文，黄林清，等．薏苡仁多糖对实验性2型糖尿病大鼠IR的影响．中国糖尿病杂志，2002，10(1)：44-4 8．
[87]郭洁文，潘竞锵，邱光清，等．荔枝核增强2型糖尿病-IR大鼠胰岛素敏感性作用．中国新药杂志，2003，12 (7)：526-529．
[88]徐卫东，林君如，朱姗颖，等．复方苦瓜饮对2型糖尿病大鼠模型IR的影响．江苏大学学报(医学版)，2003，13(2)：99-100．
[89]Vikrant V,Grover JK,Tandon N.Treatment with extracts of momordic a charantia and Eugenia jambolana prevents hyperglycemia and hyperin sulinemia in fructose fed rats.J Ethnopharmacol,2001,76(2):139-143.
[90]王芬，万金兰，陈坤，等．苦瓜对IR鼠肾组织中一氧化氮合成酶的影响．湖北预防医学杂志，2003，14(6)：19-22．
[91]赵慧娟，陶正贤，龙明智，等．姜黄素对MS大鼠血浆TNF-α和血清sICA M-1水平的影响．中国康复医学杂志，2006，21(7)：599-601．
[92]何泮，曾庆明等．清化消瘀方对MS患者PPARγ、Leptin、TNF-α表达的干预研究[J]．中国中医急症，2008，17(12)：1691-1698
[93]熊曼琪，林安钟，朱章志，等．加味桃核承气汤对Ⅱ型糖尿病大鼠IR的影响．中国中西医结合杂志，1997，17(3)：165-168．
[94]王开成，方朝晖．丹蛭降糖胶囊对IR大鼠脂联素的影响．江西中医学院学报，2006，18(2)：61-63．
[95]方朝晖，鲍陶陶，王开成，等．丹蛭降糖胶囊对糖尿病IR大鼠骨骼肌葡萄糖转运体基因表达的影响．中国实验方剂学杂志，2006，12(6)：32-35．
[96]方朝晖，王佑民，王开成，等．丹蛭降糖胶囊对IR大鼠PPAR-γ mRNA表达的影响．中国实验方剂学杂志，2006，12(4)：36-39．
[97]王开成，方朝晖．丹蛭降糖胶囊对IR大鼠抵抗素的影响．中国中医药信息杂志．2006，13(7)：27-29．
[98]付雪艳，董琳等．玉液汤对IR大鼠脂肪细胞因子的影响．时珍国医国药结合杂志[J]，2008，19(6)：534～536
[99]化瘀降浊合剂对MS患者糖脂代谢的影响．天津中医药[J]，2008，25(5)：364～366
[100]李怡，张前进，李秋贵，等．糖肾胶囊对FFRIR性与leptin浓度的影响．中国实验方剂学杂志，2000，6(1)：25-27．
[101]赵旭燕，李玉明，王波．糖脂消对IR性高血压大鼠IR性和血清瘦素水平的影响．中国慢性病预防与控制，2004，12(1)：6-8．
[102]司晓晨，潘杨，尚斌．胰敏胶囊治疗果糖诱导大鼠的IR．福建中医药，2003，34(5)：43-46．
[103]程海波，尚文斌，司晓晨．胰敏胶囊阻止高脂膳食诱导大鼠IR的发生．南京中医药大学学报，2003，19(5)：281-284．
[104]王智明，李道本，陈璐璐，等．调肝泻火汤防治大鼠IR的实验研究．中国中西医结合消化杂志，2002，10(2)：81-83．
[105]叶爱丽，陆付耳，徐丽君．黄连解毒汤对IR大鼠脂肪组织胰岛素受体及其底物信号转导的影响．中国中西医结合杂志，2006，26(10)：909-912．
[106]李莉芬，王世东，姜淼，等．人参黄连对2型糖尿病IR大鼠糖脂代谢的影响．中国中医基础医学杂志，2006，12(9)：707-708．
[107]高琳琳等．中药保护血管内皮细胞结构和功能的研究进展．中国AS杂志，2006，14(10)：907-910．
[108]王虹，刁清，周敬．代谢紊乱患者脂联素水平和血管内皮细胞功能的变化[J]．疑难病杂志，2006，6(6)：327-328
[109]韩永明，袁芳，段研君，等．翻白草对糖尿病大鼠血管内皮细胞形态结构的影响[J]．中医药学刊，2005，23(9)：1614-1615．
[110]闵存云，刘和强，詹锋，等．牡丹皮对糖尿病大鼠PGI2、TXA2、ET、NO的影响[J]．中药材，2007，30(6)：687-689．
[111]洪峻峰，房文睁，，戴西湖．复方夏枯草汤对肝火亢盛证高血压病患者血管内皮依赖性舒张功能影响的临床研究[J]．福建中医药，2007，38(4)：1-2．
[112]赵萍，陈洁，洪永炖，等．温胆泄浊法对痰浊型高血压病患者血管内皮舒张功能与粥样硬化改善作用的超声研究[J]．中国中西医结合杂志，2007，27(1)：21-23．
[113]阎艳丽，吉梅，宋晓宇，等．当归芍药散对血脂异常大鼠抗氧化能力及动脉壁VCAM-1基因表达的影响[J]．中国实验方剂学杂志，2007，13(2)：25-28．
[114]马鲁波，刘剑刚，史大卓，等．气血并治方及其配伍对高脂血症血瘀大鼠血管活性物质的影响[J]．中国实验方剂学杂志，2006，12(4)：32-35．
[115]杨玉莲，孙新宇．加减黄连温胆汤加味治疗肥胖型消渴30例[J]．中医研究，2007，20(4)：48-49．
[116]白清．加减黄连温胆汤加味治疗痰瘀型糖尿病47例[J]．河南中医，2004，24(12)：61．
[117]张娟，张媛，张永声．加减黄连温胆汤治疗糖尿病酮症酸中毒40例[J]．山东中医学院学报，1995，19(4)：245-246．
[118]乔玉秋，谢茂玲．加减黄连温胆汤配合西药治疗糖尿病酮症酸中毒26例[J]．浙江中医杂志，2000，35(3)：112．
[119]戴其军．加减黄连温胆汤加味治疗MS32例[J]．吉林中医药，2007，27(11)：24-25．
[120]黄斌，王文霞，朱明军．加减黄连温胆汤加味治疗心律失常72例[J]．辽宁中医杂志，2000，27(8)：353-354．
[121]秦玖刚．加减黄连温胆汤加味治疗病毒性心肌炎80例[J]．四川中医，2005，23(6)：46-47．
[122]李毅，姜辉，张丽君．加减黄连温胆汤配合生脉散治疗病毒性心肌炎228例疗效观察[J]．云南中医中药杂志，2005，26(2)：29．
[123]杨小乐．加减黄连温胆汤加减治疗室性早搏[J]．中国中医急症，2005，14(4)：331．
[124]呼永河，李静，武娜杰，等．加味加减黄连温胆汤治疗糖尿病无症状心肌 缺血的临床观察[J]．中国中西医结合杂志，2005，25(9)：790-793．
[125]邹勇．加减黄连温胆汤治疗冠心病心绞痛30例[J]．山东中医药大学学报，1999，23(5)：363-364．
[126]洪杰斐．加减黄连温胆汤加味治疗心脏神经官能症48例[J]．四川中医，2000，18(9)：23-24．
[127]林毅，张若楠．葛根素研究概况[J]．黑龙江中医药，2000，4：56．，
[128]王金红，高尔，孙善明，等．乳化葛根素对高脂血症家兔模型调血脂和抗氧化作用[J]．潍坊医学院学报，2001，23(1)：6．
[129]Feng-Lin Hsu,I-Min Liu,Daih-Huang Kuo,et al.Antihyperglycem ic Effect of Puerarin in Streptozotocin-Induced Diabetic Rats[J].J:Nat.Prod,2003,66:788.
[130]朱庆磊，何爱霞，吕欣然．葛根素对氧自由基的清除和抗氧化性损伤作用[J]．解放军药学学报，2001，17(1)：1-4．。
[131]党海霞．黄芪治疗糖尿病的药理研究近况[J]．中医药学报，2002，30(3)：69～71
[132]吕翠婷，黎海衫，等．中药决明子研究进展．食品科技，2006，15(8)：295
[133][9]Umesh KP,Saraf S,Dixi VK.Hypolipidemic activity of seeds Cassia tora Linn.Journal of ethnopharmacology,2004,90:249-252
[134]黄迎春，等．中药决明子的研究进展[J]．食品科技，2006，12(8)：295～298。
[135]AuTS,Yang DJ,Zhang YO,et al.Differential expression of lipi d metabolism related genes in HepG2 cells treated with neotorala ctone.Acta Pharmaceutica Sinica,2003,38。 (1):62-66
[136]邵致格．丹参对营养性肥胖大鼠代谢异常的预防作用．东南大学硕士论文
[137]杨萍土编，简明实验动物学IM]．上海：复旦人学出版社，2003年，P14．3
[138]李建生，赵敏，余海滨，等．代谢综合征大鼠模型的建立与评价及增龄因素的影响[J]．中国老年学杂志，2005，25(12)：1490-1492．
[139]Johnson MD,Zhang HY,Kotchen TA.Sucrose does not raise blood pressure in rats maintained on a low salt intake[J].Hypertension,1993,106(12):779-85.
[140]曹廷兵，闫振成，沈成义，王利娟，聂海，钟健，等．代谢综合征大鼠模型的建立及其相关基因表达变化的研究[J]．解放军医学杂志，2005，30(8)：702-705
[141]Kim JY,Nolte LA,Hansen PA,Han DH,Kevin F,Thompson PA, et al.High-fat diet-induced muscle insulin resistance:relationship to visceral fat mass[J].AM J Physiol Regulatory Integrative Comp Phys iol,2000,279(6):R2 057-065 Naderali EK,Estadella D,Rocha M,Pi ckavance LC,Fatani S,Denis RG,et al.A fat-enriched,glucose-enric hed dietmarkedly attenuates adiponectinm R-NAlevels in rat epididyma 1 adipose tissue[J].Clin Sci,2003,105(4):403-408
[142]程志清．胰岛素和瘦素抵抗高血压肥胖相关的研究[J]．浙江中医学院学报，2006，30(1)：57
[143]孙振球，徐勇勇，医学统计学，北京，第二版(2005)，28-30
[144]刘荣，孙长预，李颖，等．饮食诱导肥胖抵抗和肥胖人鼠血中激素水平的比较[J]．卫生研究，2003，32(3)：212-214，
[145]Anca D.Dobrian,Michael J.Davies,Russell L.Prewitt,etal.Development of hypertension in a rat model of diet-induced obesity.Hypertension,2000,35:1009-1015:
[146]卜石，扬文英，王昕，等。长期高脂饲养对大鼠葡萄糖刺激的胰岛素分泌的影响。中华内分泌代谢杂志，2003，19：25-28
[147]Bo I,Peter A,Tiinamaija T,et al.Cardiovascular Morbidity and Mort ality Associated With the Metabolic Syndrome.Diabetes Care 2001,24:683-689,
[148]Daubressse JC,Cadiere GB,Sternon J.Obesity in adult patients:check up and treatment[J].Rev Med Brux,2005,26(1):33-42.
[149]Carlsen SM,Rossvoll O,Bjeve KS,et al.Metformin improves bl ood lipid patern in nondiabetic patients with coronary heart disease.J I ntern Med 1996;239(3):227-235
[150]邓宏明，肖常青，夏宁，等．二甲双胍治疗2型糖尿病人对血压影响的研究[J]．高血压杂志2002，10(3)：197-10
[151]邵新宇，贾伟平．腹内脂肪与代谢综合征[J]．中华内分泌代谢杂志，2004，20 (3)：279-282
[152]L(?)szl(?)B.Tank(?),Yu Z.Bagger,Peter Alexandersen,et al.Peripheral Adi posity Exhibits an Independent Dominant Antiatherogenic Effect in Eld erly Women.Circulation,2003,107:1626-1631
[153]Trayhurn P,Beattie JH.Physiological role of adipose tissue:white adipose tissue as an endocrine and secretory organ.Proc Nutr Soe,2001,60:329-339.
[154]L(?)szl(?)B.Tank(?),Yu Z.Bagger,Peter Alexandersen,et al.Peripheral Adi posity Exhibits an Independent Dominant Antiatherogenic Effect in Eld erly Women.Circulation,2003,107:1626-1631
[155]Raij L.Workshop:hypertension and cardiovascular risk factors:rol e of the angiotensinⅡ-nitric oxide interaction.Hypertension.2001,37(2 Part 2):767-773
[156]Candales A.Metabolic syndrome X:a comprehensive review of th e Pathophysiology and recommended therapy.J Med 2001,32:283-300
[157]Matthews 等 Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment:insulin resistance and beta-1 cell function from fast ing plasma glucose and insulin concentration in man.Diabetologia,1985,28:412-419.
[158]Haffner S,Gonzaler C,Miettinen A,et al.A prospective analysis of t he Homa model.the Mexico City Diabetes Study.Diabetes Care,1996,19:1138-1141.
[159]程桦．代谢综合征临床研究进展．新医学，2003，5(34)：330-333
[160]胡艳，凌文华．炎症与代谢综合征[J]．国外医学内科学分册，2006，33(11)：493-496．
[161]Flier JS,Scherer PE.Adiposetissue:from lipid storagecom Partme nt to endocrine organ[J].Diabetes,2005,54(suppll):627.
[162]Grundy SM,Brewer Jr H B,Cleeman JI,et al.Definition of met abolic syndrome.Report of the National Heart,Lung,and Blood Instit ute/Ameriean Heart Association Conference on Scientific Issues Related to Definition.Circulation 2004,109:433,Ridker PM,Buring JE,Co ok NR,et al.C-reactive protein,the metabolic syndrome,and risk of incident cardiovascular events:an 8-year follow-up initially healthy Am erican women.Circulation 2003,107(3):391-39.
[163]Libby P,Ridker PM,MaseriA.Inflammation and atherosclerosis
[164]Lau DC,Dhillon B,Yan H,et a.l Adipokines:molecular links
[165]王继贵，在心血管疾病时内皮功能的循环标志物[J]．江西医学检验2007，2(25)：51-54
[166]漆泓，孙明，周宏研．MS患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系．临床内科杂志，2003，20(7)：353-355．
[167]Vetter R,Lombardi AM,Fabris R,et al.Substrate competition and ins ulin action in animal models.Int J Obes Relat metab Disord,2000,24[Suppl 2]:S22-24.
[168]刘超，周红文．瘦素和代谢综合征．辽宁实用糖尿病杂志，2002，10(4)：2-4．
[169]Assali AR,Ganor A,Beigel Y,et al.Insulin resistance in obesity:bod y weight or energy balance?J Endocrinol,2001,171(2):293.
[170]李东锋，杨汉东，杨波，等．代谢综合征患者血清瘦素与血脂、肥胖及胰岛素抵抗关系的研究．实用医学杂志．2005，21(17)：1911-1913．
[171]张俊清，高研，郭晓惠，等．肥胖青少年血清瘦素、胰岛素和胰岛素原水平的变化．中华内科杂志，2002，41(4)：221-223．
[172]Fried SK,Zechner R.Cachection/tumor necrosis factor decreases hu man adipose tissue lipoprotein lipase mRNA levels,synthesis and activit y.J Lipid Res,1989,30:1917-1923.
[173]Kern PA,Saghizadeh M,Ong JM,et al.The expression of TNF-αin hu man adipose tissue regulation by obesity,weight loss and relationship t o lipoprotein lipase.J Clin Invest,1995,95:2111-2119.
[174]Prins JB,Niesler CV,Winterford CM,et al.Tumor necrosis factor-αin duced apotosis of human adipose cell.Diabetes,1997,46:1939-1944.
[75]鲁瑾，邹大进，张家庆．肿瘤坏死因子-α致胰岛素抵抗．中国病理生理杂志，1999，15(12)：1146-1148．
[176]顾鸣宇，盛正妍．胰岛素抵抗与脂肪肝．国外医学内分泌分册，2003，23(增刊)：32-33．
[177]Papanicolaou,DA,Vgontzas,AN.Interleukin-6:the endocrine cyt okine.J Clin Endocrinol Metab,2000,85(3):1331-1333
[178]Mohamed-Ali V,Flower L,Sethi J,et al.Beta-adrenergic regulati on of IL-6 release from adipose tissue:in vivo and in vitro studies.J Clin Endocrinol Metab,2001,86(12):5864-5869.Steensberg A,Keller C,Starkie RL,et al.IL-6 and TNF-alpha:expression in,and release from,contracting human skeletal muscle.Am J Physiol Endocrinol Metab,2002,283 (6):E1272-E1278
[179]Mohamed-A li V,Goodriek S,Rawesh A,et al.subcutaneous adipo se tissue releases interleukin-6,but not tumornecrosis factor-α,in vivo.J Clin Endocrinol Metab,1997,82(12):4196-4200
[180]Jens MB,Camilla V,Toubro S,et al.Association between measur es of insulin sensitivity and circulating levels of interleukin-8,interle ukin-6 and tumor necrosis factor-α,effect of weight loss in obese men.Eur J Endocrinol,2003,148(5):535-542
[181]S.K.Fried,D.A.Bunkin,A.S.Greenberg,Omental and subcutaneou s adipose tissues of obese subjects release interleukin-6:difference an d regulation by glucocorticoid,J.Clin.Endocrinol.Metab.1998,83(3)1145-1158
[182]Pradhan AD,Manson JE,Rifai N,et al.C-reactive protein,interl eukin 6,and risk of developing type 2 diabetes mellitus.JAMA,2001, 286(3):327-334
[183]Vozarova B,Weyer C,Hanson K,et al.Circulating interleukin-6 in relation to adiposity,insulin action,and insulin action,and insulin secretion.Obes Res 2001,9(7):414-417
[184]Bastard JP,Jardel C,Bruckert E,et al.Elevated levels of interle ukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.J Clin Endocrinol Metab.2000.85(9):3338-3342
[185]Bastard JP,Maachi M,Van Nhieu JT,et al.Adipose tissue IL-6 c ontent correlates with resistance to insulin activation of glucose uptak e both in vivo and in vitro.J Clin Endocrinol Metab,2002,87(5):2084-2089
[186]Kralisch S,SommerG,DeckertCM,eta.l Adipokines in diabetes and cardiovascular diseases[J].Minerva Endocrino,l 2007,32(3):161-171.
[187]Wassink AM,Olijhoek JK,Visseren FL.The metabolic syndrome:metaboli changes with vascular consequences[J].Eur JClin Inves,t 2007,37(1):8-17.
[188]Nedv(?)dkov(?)J,SmitkaK,Kopsk V,eta.l Adiponectin:an adipocyte-d erived protein[J].PhysiolRes,2005,54(2):133-140.
[189]MatsuzawaY,FunahashiT,NakamuraT.Molecularmechanism ofmetabolic syndromeX:contribution of adipocytokines adipocyte-derived bioactive substance[J].AnnNY Acad Sc,i 1999,892(10):146-154.
[190]D(?)ez JJ,IglesiasP.The role of the novel adipocyte-derived hormon e adiponectin in human disease[J].Eur J Endocrino,2003,148(3):293-300.
[191]Vasseur F,Lepr(?)tre F,LacquemantC,et a.l The genetics of adipo nectin[J].CurrDiab Rep,2003,3(2):151-158.
[192]赵宝珍等．罗格列酮对糖耐量受损大鼠血清脂联素和肝脏脂联素受体表达的影响[J]．中国药物与临床2008，(8)5：351-354．
[193]郭新民，王桂云等．翻白草对2型糖尿病大鼠脂联素基因表达的影响[J]．牡丹江医学院学报 2007，(28)5期3-5．